By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > GMJ Briefs > How One Protein Drives Parkinson’s Disease Spread Between Brain Cells

How One Protein Drives Parkinson’s Disease Spread Between Brain Cells

GMJ
Last updated: 28/06/2026 04:47
By
Prof. Giorgi Pkhakadze
Share
1 Min Read
Scientific illustration showing GPNMB protein interaction between brain cells in Parkinson's disease research
Scientists have identified GPNMB, a protein that helps Parkinson's disease spread through the brain by creating a destructive cycle between immune cells and neurons. Early antibody treatments successfully blocked this process in laboratory experiments. — Photo by Tara Winstead on Pexels (Pexels License)
SHARE
1 min read|113 words

A critical finding in neurodegenerative research reveals how GPNMB protein creates a destructive cycle in Parkinson’s disease. When neurons suffer damage, immune cells initiate a protective response by releasing GPNMB. However, this mechanism backfires—the protein actively facilitates transfer of toxic alpha-synuclein aggregates from damaged cells to healthy neurons, perpetuating damage in a spreading pattern. Laboratory studies demonstrate that blocking GPNMB with antibody treatment successfully halted this pathological progression in experimental conditions. This mechanism explains the characteristic pattern of Parkinson’s advancement through distinct brain regions over time. The discovery provides researchers with a specific molecular target for therapeutic intervention, potentially enabling disease-modifying treatments that interrupt the propagation cycle rather than simply alleviating symptoms.

Was this article helpful?

GMJ Brief · Key Finding

📰 Read the full article: Blocking Key Protein GPNMB Shows Promise in Halting Parkinson’s Disease Spread →

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
New AI Model Strips Personal Data From ECGs While Preserving Heart Risk Information

Artificial intelligence can extract age, sex, race, and individual identity from standard…

AI-Guided Ultrasound Predicts Bubble Collapse to Improve Brain Barrier Opening

Researchers at Georgia Institute of Technology have developed an AI system that…

Orforglipron Shows Clinically Significant HbA1c Reductions in Type 2 Diabetes

Two phase III randomised controlled trials presented at the American Diabetes Association…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Medical professionals reviewing hantavirus transmission data and emergency response protocols

UKHSA Establishes First Standardized Framework for Hantavirus Emergency Response

By
Prof. Giorgi Pkhakadze
06/07/2026

PHEIC Declaration: Ebola Cross-Border Transmission DRC-Uganda

By
Prof. Giorgi Pkhakadze
31/05/2026
Medical isolation ward with healthcare workers in protective equipment

Brazil Activates Emergency Protocol as Two Patients Present With Ebola-Like Symptoms

By
Prof. Giorgi Pkhakadze
08/06/2026
Laboratory mice study examining effects of sugar-free versus moderate sugar diets on metabolic health

New Research Challenges Sugar Elimination: Balanced Nutrition May Trump Extreme Restriction

By
Prof. Giorgi Pkhakadze
06/07/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up